Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Input: Consider Input: Paragraph: The Illinois Department of Veterans Affairs and the Illinois Department of Public Health are reviewing the case of the resident with the flu-like illness. Officials say the resident of the home 312 miles (500 kilometers) southwest of Chicago has received medical treatment and is recovering. Officials say no other cases of the illness contracted by breathing infected water vapor have been identified. Staff members are monitoring residents for respiratory illnesses. Officials have notified residents, staff members, and relations and representatives of residents. The last case of Legionnaires’ at Quincy was in 2018. An outbreak that began in 2015 caused the deaths of 13 residents and sickened dozens more. Then-Gov. Bruce Rauner faced withering criticism for not doing enough in response to the crisis. Claim: Legionnaires’ case identified at Quincy veterans’ home.

Output: Gov. J.B. Pritzker’s administration is investigating a case of Legionnaires’ diseases at the veterans’ home in Quincy, the site of 13 deaths from the malady starting with a 2015 outbreak.


Input: Consider Input: Paragraph: A panel of Food and Drug Administration advisers voted unanimously in favor of Amgen’s version of AbbVie’s Humira, a biotech drug that raked in nearly $15 billion last year, according to IMS Health. While not binding, the recommendation likely paves the way for FDA approval of the knockoff drug. For years, biotech drugs faced no competition because there was no regulatory way to approve copycat versions, even after patents had expired. If approved, Amgen’s drug would join a new wave of so-called biosimilars, which have the potential to generate billions in savings for U.S. insurers, doctors and patients. But it could take years for those savings to arrive. Evercore ISI analyst Mark Schoenebaum says the earliest Amgen could launch its product would be March 2017, though that would risk infringing patents which Abbvie says protect its drug until at least 2022. Wall Street analysts expect the patent issue to be fought in court, and then for Amgen’s drug to launch sometime between 2018 and 2022. First approved in 2002, Humira has long been among the most profitable drugs in the world. It accounted for 60 percent of Abbvie’s total revenue last year. The injectable drug, which blocks chemicals linked to inflammation, is approved for multiple uses, including rheumatoid arthritis, Crohn’s disease and psoriasis. Thousand Oaks, Calif-based Amgen is seeking FDA approval to market its version, known only as ABP 501, for seven diseases. Amgen is itself a biotech powerhouse, and it too has medications facing competition from cheaper versions. The company is working to hedge those loses by developing lower-cost versions of competitors’ drugs. Biotech drugs are powerful, injected medicines produced in living cells that are typically much more expensive than traditional, chemical-based drugs. In 2015, six of the 10 top-selling medicines globally were biotech drugs, with more than $56 billion in combined sales. The FDA only approved the first lower-cost biotech drug last March, a Novartis version of the Amgen drug Neupogen. Pfizer won approval to market a second biosimilar in April, a version of Johnson & Johnson’s Remicade, but it is not yet for sale. Questions remain about just how much savings U.S. biosimilars will deliver. Novartis’ Zarxio sells for 15 percent less than the original Neupogen. Experts predict biosimilar discounts of 15 percent to 30 percent in the U.S. In Europe, where governments regulate prices, discounts are higher. Development of lower-cost anti-inflammatory drugs like Humira is considered pivotal in reducing U.S. spending on specialty drugs, which has doubled to $150 billion since 2010, according to IMS Health. On Wednesday, the same panel of FDA advisers will review a Novartis version of Enbrel, which is marketed by Amgen. Claim: Lower-cost biotech drug gets thumbs up from FDA panel.

Output: The second-biggest selling drug in the world could get some cheaper competition in the U.S., after a federal panel endorsed an alternative version of the pricey medication used to treat rheumatoid arthritis and other inflammatory diseases.


Input: Consider Input: Paragraph: Most lawmakers will spend the week in their home districts but a select few will gather in New York City for a hearing on what experts say is a looming crisis in home health care services. When the full Legislature returns Feb. 28, lawmakers can look forward to a month of backroom negotiations over the state budget. Democratic Gov. Andrew Cuomo has proposed a $152 billion spending plan. Lawmakers hope to agree on a final budget before April 1, the start of a new fiscal year. Another unresolved issue is Uber’s request to expand upstate. Ride-hailing services Uber and Lyft are both prohibited from operating outside of New York City. ___ This story has been corrected to show the home health care services hearing in in New York City, not Albany. Claim: This Week from Albany: Break before budget work.


Output: In New York state government news, the Legislature is taking a break before work on the state budget heats up.